Difference between revisions of "Ribociclib (Kisqali)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
m |
||
| Line 14: | Line 14: | ||
==Also known as== | ==Also known as== | ||
| − | LEE011, LEE-011 | + | *'''Code names:''' LEE011, LEE-011 |
| + | *'''Brand name:''' Kisqali | ||
==References== | ==References== | ||
| Line 20: | Line 21: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Revision as of 15:12, 3 December 2017
General information
Class/mechanism: Cyclin-dependent kinase (CDK) 4 and 6 inhibitor. Ribociclib inhibits DNA synthesis and cancer cell growth by blocking activity of the cyclin D-CDK4/6 complex which regulates cell cycle progression and cellular proliferation by phosphorylating the retinoblastoma protein (pRb). Inhibiting pRb phosphorylation has been observed to lead to cell cycle arrest in the G1 phase.[1][2][3]
Route: PO
Extravasation: n/a
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 3/13/2017: Initial FDA approval "in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer."
Also known as
- Code names: LEE011, LEE-011
- Brand name: Kisqali